Journal of Gastroenterology

, Volume 49, Issue 11, pp 1485–1494 | Cite as

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

  • Noritomo Shimada
  • Hidenori Toyoda
  • Akihito Tsubota
  • Tatsuya Ide
  • Koichi Takaguchi
  • Keizo Kato
  • Masaki Kondoh
  • Kazuhiro Matsuyama
  • Takashi Kumada
  • Michio Sata
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy. However, the association between SVR and viral kinetics earlier than week 4 after initiation of therapy remains unclear. Thus, we evaluated the SVR prediction ability of baseline factors and reduced hepatitis C virus (HCV) RNA levels at week 1 after the initiation of TVR-based therapy in Japanese genotype-1b chronic hepatitis C (CHC) patients.

Methods

A total of 156 Japanese CHC patients received a 24-week regimen of TVR-based therapy. Baseline factors and reduction in HCV RNA levels at weeks 1 and 4 after the initiation of therapy were analyzed for SVR prediction.

Results

Multiple logistic regression analysis for SVR in TVR-based therapy identified the IL28B TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1, RVR, and treatment-naïve/relapse. Whereas the SVR rate was higher than 90 % regardless of the reduction in HCV RNA levels at week 1 in patients with the TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1 was the strongest predictor of SVR in patients with the non-TT genotype, as determined by multiple logistic regression analysis (P = 0.0043).

Conclusions

The IL28B TT genotype is the most important baseline factor for predicting SVR, and a ≥4.7 log10IU/mL reduction in HCV RNA at week 1 is a useful very early on-treatment predictor of SVR, especially in the non-TT genotype.

Keywords

Chronic hepatitis C Reduction in HCV RNA at week 1 Telaprevir IL28B 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ghany MG, Nelson DR, Strader DB, American Association for Study of Liver Diseases, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    McHutchison JG, Everson GT, Gordon SC, PROVE1 Study Team, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Hézode C, Forestier N, Dusheiko G, PROVE2 Study Team, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.PubMedCrossRefGoogle Scholar
  5. 5.
    McHutchison JG, Manns MP, Muir AJ, PROVE3 Study Team, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.PubMedCrossRefGoogle Scholar
  6. 6.
    Zeuzem S, Andreone P, Pol S, REALIZE Study Team, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.PubMedCrossRefGoogle Scholar
  7. 7.
    Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204:84–93.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54:1538–46.PubMedCrossRefGoogle Scholar
  9. 9.
    Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 2012;84:1097–105.PubMedCrossRefGoogle Scholar
  10. 10.
    Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Muir AJ. IL28B in the era of direct-acting antivirals for hepatitis C. J Clin Gastroenterol. 2013;47:222–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Pol S, Aerssens J, Zeuzem S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol. 2013;58:883–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Akuta N, Suzuki F, Fukushima T, et al. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with HCV genotype 1. J Clin Microbiol. 2013;51:2862–8.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Tsubota A, Shimada N, Atsukawa M, et al. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with HCV genotype 1b. J Gastroenterol Hepatol. 2013 (Epub ahead of print).Google Scholar
  16. 16.
    Shimada N, Tsubota A, Atsukawa M, et al. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. J Med Virol. 2013 (Epub ahead of print).Google Scholar
  17. 17.
    Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRefGoogle Scholar
  20. 20.
    Tsubota A, Shimada N, Yoshizawa K, et al. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int. 2012;32:826–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Toyoda H, Kumada T, Shimada N, et al. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. J Med Virol. 2013;85:65–70.PubMedCrossRefGoogle Scholar
  22. 22.
    Toyoda H, Kumada T, Shimada N, et al. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis. 2012;12:324.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Yoshizawa K, Abe H, Aida Y, et al. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. J Med Virol. 2013;85:1180–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the management of hepatitis C virus infection: first edition, May 2012. The Japan Society of Hepatology. Hepatol Res. 2013;2013(43):1–34.CrossRefGoogle Scholar
  27. 27.
    Jacobson IM, McHutchison JG, Dusheiko G, ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.PubMedCrossRefGoogle Scholar
  28. 28.
    McHutchison JG, Lawitz EJ, Shiffman ML, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Sherman KE, Flamm SL, Afdhal NH, ILLUMINATE Study Team, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24.PubMedCrossRefGoogle Scholar
  30. 30.
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20.CrossRefGoogle Scholar
  31. 31.
    Simmonds P, Mellor J, Sakuldamrongpanich T, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol. 1996;77:3013–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;11(334):77–81.CrossRefGoogle Scholar
  35. 35.
    Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2013 (Epub ahead of print).Google Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Noritomo Shimada
    • 1
  • Hidenori Toyoda
    • 2
  • Akihito Tsubota
    • 3
  • Tatsuya Ide
    • 4
  • Koichi Takaguchi
    • 5
  • Keizo Kato
    • 1
  • Masaki Kondoh
    • 6
  • Kazuhiro Matsuyama
    • 6
  • Takashi Kumada
    • 2
  • Michio Sata
    • 4
  1. 1.Division of Gastroenterology and HepatologyShinmatsudo Central General HospitalMatsudoJapan
  2. 2.Department of GastroenterologyOgaki Municipal HospitalOgakiJapan
  3. 3.Institute of Clinical Medicine and ResearchJikei University School of MedicineKashiwaJapan
  4. 4.Division of Gastroenterology, Department of MedicineKurume University School of MedicineKurumeJapan
  5. 5.Department of HepatologyKagawa Prefectural Central HospitalTakamatsuJapan
  6. 6.Department of Life Cycle ManagementRoche Diagnostics K.KTokyoJapan

Personalised recommendations